Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 3, 2009, Pages 429-435

  Suzuki, Yoshiyuki ^a,b   Suzuki, Fumitaka ^b   Kawamura, Yusuke ^b   Yatsuji, Hiromi ^b   Sezaki, Hitomi ^b   Hosaka, Tetsuya ^b   Akuta, Norio ^b   Kobayashi, Masahiro ^b   Saitoh, Satoshi ^b   Arase, Yasuji ^b   Ikeda, Kenji ^b   Kobayashi, Mariko ^a   Miyakawa, Yuzo ^c   Kumada, Hiromitsu ^b  

^a TORANOMON HOSPITAL   (Japan)

^b Department of Hepatology ^*  (Japan)

^c Miyakawa Memorial Research Foundation   (Japan)

Author keywords

Chronic hepatitis; Entecavir; Hepatitis B virus; Lamivudine; YMDD mutants

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL;

EID: 63049107827     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2008.05760.x     Document Type: Article

References (27)

1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003 362 : 2089 94.
2. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999 341 : 1256 63.
3. Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998 339 : 61 8.
4. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998 27 : 1711 16.
5. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 1997 26 : 1393 5.
6. Leung NW, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001 33 : 1527 32.
7. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999 30 : 567 72.
8. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003 348 : 800 7.
9. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003 348 : 808 16.
10. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1001 10.
11. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006 354 : 1011 20.
12. Suzuki F, Joji T, Yoshiaki K et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients. J. Gastroenterol. Hepatol. 2008 23 : 1320 6.
13. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 : 81 90.
14. Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006 130 : 2039 49.
15. Usuda S, Okamoto H, Iwanari H et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J. Virol. Methods 1999 80 : 97 112.
16. Usuda S, Okamoto H, Tanaka T et al. Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product. J. Virol. Methods 2000 87 : 81 9.
17. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 1977 74 : 5463 7.
18. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006 44 : 1656 65.
19. Zoulim F. Entecavir: a new treatment option for chronic hepatitis B. J. Clin. Virol. 2006 36 : 8 12.
20. Lampertico P. Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. J. Hepatol. 2006 45 : 457 60.
21. Lai CL, Rosmawati M, Lao J et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002 123 : 1831 8.
22. Suzuki Y, Arase Y, Ikeda K et al. Histological improvements after a three-year lamivudine therapy in patients with chronic hepatitis B in whom YMDD mutants did not or did develop. Intervirology 2003 46 : 164 70.
23. Suzuki Y, Kumada H, Ikeda K et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J. Hepatol 1999 30 : 743 8.
24. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect. Dis. 2008 8 : 167 78.
25. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 2007 51 : 902 11.
26. Lampertico P, Vigano M, Manenti E et al. M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 : 1445 51.
27. Yatsuji H, Suzuki F, Sezaki H et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol 2008 48 : 923 31.